Exon skipping induced by CRISPR-directed gene editing regulates the response to chemotherapy in non-small cell lung carcinoma cells

We have been developing CRISPR-directed gene editing as an augmentative therapy for the treatment of non-small cell lung carcinoma (NSCLC) by genetic disruption of Nuclear Factor Erythroid 2-Related Factor 2 (NRF2). NRF2 promotes tumor cell survival in response to therapeutic intervention and thus i...

Full description

Saved in:
Bibliographic Details
Published in:Gene therapy 2022-06, Vol.29 (6), p.357-367
Main Authors: Banas, Kelly, Modarai, Shirin, Rivera-Torres, Natalia, Yoo, Byung-Chun, Bialk, Pawel A., Barrett, Connor, Batish, Mona, Kmiec, Eric B.
Format: Article
Language:English
Subjects:
13/106
13/109
14/32
38/1
38/22
38/23
38/90
45/41
45/77
631/337
631/337/572
631/67/1612/1350
Biomedical and Life Sciences
Biomedicine
Cell Biology
Cell survival
Chemotherapy
CRISPR
Enhancers
Exon skipping
Gene Expression
Gene Therapy
Genome editing
Human Genetics
Lung cancer
Lung carcinoma
Nanotechnology
Non-small cell lung carcinoma
Small cell lung carcinoma
Solid tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have been developing CRISPR-directed gene editing as an augmentative therapy for the treatment of non-small cell lung carcinoma (NSCLC) by genetic disruption of Nuclear Factor Erythroid 2-Related Factor 2 (NRF2). NRF2 promotes tumor cell survival in response to therapeutic intervention and thus its disablement should restore or enhance effective drug action. Here, we report how NRF2 disruption leads to collateral damage in the form of CRISPR-mediated exon skipping. Heterogeneous populations of transcripts and truncated proteins produce a variable response to chemotherapy, dependent on which functional domain is missing. We identify and characterize predicted and unpredicted transcript populations and discover that several types of transcripts arise through exon skipping; wherein one or two NRF2 exons are missing. In one specific case, the presence or absence of a single nucleotide determines whether an exon is skipped or not by reorganizing Exonic Splicing Enhancers (ESEs). We isolate and characterize the diversity of clones induced by CRISPR activity in a NSCLC tumor cell population, a critical and often overlooked genetic byproduct of this exciting technology. Finally, gRNAs must be designed with care to avoid altering gene expression patterns that can account for variable responses to solid tumor therapy.
ISSN:0969-7128
1476-5462
DOI:10.1038/s41434-022-00324-7